PHAR - Pharming Group N.V. (PHAR) Q1 2024 Earnings Call Transcript
2024-05-12 09:19:10 ET
Pharming Group N.V. (PHAR)
Q1 2024 Earnings Conference Call
May 08, 2024, 7:30 AM ET
Company Participants
Sijmen de Vries - Executive Director and Chief Executive Officer
Stephen Toor - Chief Commercial Officer
Anurag Relan - Chief Medical Officer
Jeroen Wakkerman - Chief Financial Officer
Conference Call Participants
Christian Glennie - Stifel
Sushila Hernandez - Van Lanschot Kempen
Joe Pantginis - H.C. Wainwright
Hartaj Singh - Oppenheimer
Alistair Campbell - Royal Bank of Canada
Presentation
Operator
Good day, and thank you for standing by. Welcome to the Pharming Group N.V. Q1 2024 Results Conference Call and Webcast. At this time all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your speaker today, Sijmen de Vries. Please go ahead.
Sijmen de Vries
Thank you very much Sandra, and welcome, ladies and gentlemen, to this -- our first quarter results conference.
I'm here with my -- next slide, please. I'm here with my three colleagues, in order of speaking, Stephen Toor, our Chief Commercial Officer, who is joining us from our New Jersey office; Dr. Anurag Relan, our Chief Medical Officer, joining us from our U.S. office as well; and Jeroen Wakkerman, our Chief Financial Officer, who's based with me here in Leiden.
Before I do that, I would like to point out to the next slide, please, number three, that is the forward-looking statement slide. We will be making forward-looking statements today in our presentation, and those are based upon our current plans, and insights of the -- and situations of the current market circumstances. And of course, actual results may differ from these forward-looking statements, so you cannot necessarily rely on those.
So having said that, I would like to go to slide number four and maybe even onwards to slide number five, because you've seen my picture already. Yes. And here we are. We're building this global -- leading global rare disease biopharma company. And we have -- we do that based on three pillars. And this is a very familiar slide for you, you have seen this before....
Pharming Group N.V. (PHAR) Q1 2024 Earnings Call Transcript